liothyronine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1585	6893-02-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: liothyronine liothyronine sodium triiodothyronine liothyronin	A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. Molecular weight: 650.98 Formula: C15H12I3NO4 CLOGP: 2.33 LIPINSKI: 1 HAC: 5 HDO: 3 TPSA: 92.78 ALOGS: -4.52 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

liothyronine
liothyronine sodium
triiodothyronine
liothyronin

A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.

Molecular weight: 650.98
Formula: C15H12I3NO4
CLOGP: 2.33
LIPINSKI: 1
HAC: 5
HDO: 3
TPSA: 92.78
ALOGS: -4.52
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mcg	O
60	mcg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
May 8, 1956	FDA	KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sensitisation	487.15	14.92	120	14315	3266	63471321
Polycystic ovaries	458.82	14.92	121	14314	4350	63470237
Ejection fraction	390.63	14.92	94	14341	2312	63472275
Rhinitis allergic	347.61	14.92	122	14313	11605	63462982
Blood test abnormal	316.99	14.92	123	14312	15506	63459081
Hypothyroidism	310.39	14.92	164	14271	42468	63432119
Sleep disorder due to a general medical condition	301.80	14.92	111	14324	12077	63462510
Carpal tunnel syndrome	296.04	14.92	127	14308	20690	63453897
Sleep apnoea syndrome	288.27	14.92	138	14297	28995	63445592
Burning sensation	222.43	14.92	144	14291	54263	63420324
Cardiac disorder	208.95	14.92	135	14300	50681	63423906
Renal disorder	204.16	14.92	114	14321	32860	63441727
Ejection fraction abnormal	176.82	14.92	47	14388	1738	63472849
Fibromyalgia	161.74	14.92	139	14296	80281	63394306
Nephrectomy	160.34	14.92	42	14393	1466	63473121
Gastrooesophageal reflux disease	160.07	14.92	149	14286	95490	63379097
Asthma	151.51	14.92	165	14270	127396	63347191
Loss of personal independence in daily activities	128.13	14.92	133	14302	97157	63377430
Therapeutic product effect incomplete	120.14	14.92	145	14290	124911	63349676
Hypertension	75.76	14.92	184	14251	279119	63195468
Wheezing	70.02	14.92	97	14338	95498	63379089
Headache	66.57	14.92	302	14133	632939	62841648
Full blood count abnormal	48.37	14.92	47	14388	31670	63442917
Urine chloride decreased	39.34	14.92	8	14427	87	63474500
Hyperthyroidism	39.25	14.92	30	14405	14643	63459944
Hospitalisation	35.66	14.92	67	14368	85014	63389573
Suicidal ideation	35.12	14.92	56	14379	62365	63412222
Urine sodium decreased	34.66	14.92	8	14427	163	63474424
Thyroid function test abnormal	32.20	14.92	16	14419	3631	63470956
Drug intolerance	32.14	14.92	15	14420	308646	63165941
Systemic lupus erythematosus	31.31	14.92	5	14430	208913	63265674
Arthropathy	30.27	14.92	8	14427	234784	63239803
Glossodynia	29.90	14.92	3	14432	178873	63295714
Product substitution issue	28.80	14.92	26	14409	15970	63458617
Myopathy	28.02	14.92	22	14413	11169	63463418
Maternal exposure during pregnancy	27.43	14.92	8	14427	220054	63254533
Acute kidney injury	27.11	14.92	13	14422	263402	63211185
Palpitations	27.03	14.92	71	14364	112699	63361888
Wound	26.61	14.92	3	14432	163260	63311327
Weight increased	26.19	14.92	123	14312	260669	63213918
Feeling abnormal	22.02	14.92	79	14356	148313	63326274
Product dose omission issue	21.70	14.92	108	14327	234205	63240382
General physical health deterioration	20.62	14.92	10	14425	201392	63273195
Peak expiratory flow rate decreased	20.38	14.92	7	14428	622	63473965
Tri-iodothyronine decreased	19.84	14.92	5	14430	149	63474438
Tri-iodothyronine increased	19.84	14.92	5	14430	149	63474438
Thrombocytopenia	19.76	14.92	5	14430	151152	63323435
Product quality issue	18.57	14.92	31	14404	35834	63438753
Pre-existing condition improved	18.08	14.92	15	14420	8229	63466358
Blood thyroid stimulating hormone abnormal	18.06	14.92	7	14428	877	63473710
Blood thyroid stimulating hormone increased	17.70	14.92	14	14421	7180	63467407
Nail growth abnormal	17.41	14.92	6	14429	539	63474048
Nephropathy	17.04	14.92	13	14422	6328	63468259
Toxicity to various agents	16.65	14.92	19	14416	247231	63227356
Blood thyroid stimulating hormone decreased	15.96	14.92	11	14424	4579	63470008
Vascular parkinsonism	15.60	14.92	4	14431	128	63474459
Joint swelling	15.52	14.92	32	14403	327634	63146953
Dyspnoea	15.44	14.92	223	14212	661090	62813497

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Secondary hypogonadism	47.22	23.30	9	2017	293	34954612
Rhythm idioventricular	46.59	23.30	9	2017	315	34954590
Diffuse vasculitis	43.28	23.30	7	2019	85	34954820
Autoimmune thyroiditis	40.00	23.30	10	2016	1164	34953741
Thyrotoxic periodic paralysis	39.91	23.30	7	2019	142	34954763
Loose associations	38.54	23.30	6	2020	56	34954849
Performance enhancing product use	37.24	23.30	6	2020	71	34954834
Glucose tolerance decreased	37.08	23.30	6	2020	73	34954832
Sinus arrest	31.54	23.30	9	2017	1731	34953174
Feelings of worthlessness	28.72	23.30	6	2020	313	34954592
Pressure of speech	26.10	23.30	6	2020	489	34954416
Haematocrit increased	25.57	23.30	8	2018	2105	34952800
Insulin-like growth factor increased	25.12	23.30	7	2019	1236	34953669
Hyperthyroidism	24.35	23.30	12	2014	10554	34944351
Blood prolactin decreased	24.03	23.30	5	2021	256	34954649
Systolic hypertension	23.75	23.30	5	2021	271	34954634

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sensitisation	477.65	15.63	110	12683	3201	79728394
Polycystic ovaries	468.39	15.63	111	12682	3668	79727927
Ejection fraction	373.72	15.63	84	12709	2185	79729410
Rhinitis allergic	339.03	15.63	111	12682	12158	79719437
Carpal tunnel syndrome	306.59	15.63	116	12677	19412	79712183
Blood test abnormal	299.15	15.63	111	12682	17599	79713996
Sleep disorder due to a general medical condition	280.31	15.63	100	12693	14177	79717418
Hypothyroidism	274.23	15.63	144	12649	52248	79679347
Sleep apnoea syndrome	251.88	15.63	121	12672	36357	79695238
Burning sensation	221.38	15.63	130	12663	58502	79673093
Fibromyalgia	202.62	15.63	127	12666	64213	79667382
Cardiac disorder	192.62	15.63	124	12669	65633	79665962
Renal disorder	179.30	15.63	101	12692	42004	79689591
Ejection fraction abnormal	173.74	15.63	46	12747	2394	79729201
Gastrooesophageal reflux disease	166.32	15.63	136	12657	104110	79627485
Nephrectomy	160.79	15.63	42	12751	2073	79729522
Asthma	141.53	15.63	139	12654	134956	79596639
Loss of personal independence in daily activities	127.38	15.63	116	12677	102464	79629131
Therapeutic product effect incomplete	118.17	15.63	129	12664	141516	79590079
Hypertension	81.46	15.63	170	12623	330822	79400773
Headache	77.32	15.63	255	12538	653517	79078078
Wheezing	62.52	15.63	85	12708	116579	79615016
Hyperthyroidism	60.35	15.63	40	12753	22169	79709426
Urine chloride decreased	41.03	15.63	8	12785	101	79731494
Hospitalisation	36.53	15.63	59	12734	94177	79637418
Secondary hypogonadism	36.28	15.63	9	12784	360	79731235
Diffuse vasculitis	34.01	15.63	7	12786	118	79731477
Urine sodium decreased	33.28	15.63	8	12785	280	79731315
Thyrotoxic periodic paralysis	32.24	15.63	7	12786	154	79731441
Full blood count abnormal	32.19	15.63	36	12757	40438	79691157
Loose associations	32.14	15.63	6	12787	59	79731536
Rhythm idioventricular	31.59	15.63	9	12784	615	79730980
Glucose tolerance decreased	30.75	15.63	6	12787	76	79731519
Performance enhancing product use	30.26	15.63	6	12787	83	79731512
Tri-iodothyronine increased	28.99	15.63	7	12786	250	79731345
Insulin-like growth factor increased	28.83	15.63	11	12782	1875	79729720
Thrombocytopenia	26.90	15.63	5	12788	265254	79466341
Suicidal ideation	25.85	15.63	45	12748	76295	79655300
Blood thyroid stimulating hormone decreased	25.08	15.63	14	12779	5702	79725893
Feeling abnormal	24.20	15.63	68	12725	159131	79572464
Thyroid function test abnormal	23.45	15.63	11	12782	3123	79728472
Product dose omission issue	23.45	15.63	90	12703	247447	79484148
Myopathy	23.06	15.63	22	12771	20541	79711054
Acute kidney injury	22.79	15.63	30	12763	519374	79212221
Palpitations	20.15	15.63	55	12738	126555	79605040
Weight increased	20.14	15.63	93	12700	277293	79454302
Pyrexia	20.11	15.63	50	12743	678659	79052936
Product substitution issue	19.61	15.63	20	12773	20236	79711359
Feelings of worthlessness	19.39	15.63	6	12787	546	79731049
Anaemia	19.21	15.63	26	12767	444989	79286606
Toxicity to various agents	18.84	15.63	24	12769	421516	79310079
Nephropathy	18.27	15.63	14	12779	9724	79721871
Peak expiratory flow rate decreased	18.13	15.63	6	12787	677	79730918
Renal failure	17.95	15.63	5	12788	200963	79530632
General physical health deterioration	17.91	15.63	11	12782	275227	79456368
Autoimmune thyroiditis	17.58	15.63	10	12783	4223	79727372
Drug interaction	17.18	15.63	25	12768	415158	79316437
Vascular parkinsonism	17.08	15.63	4	12789	125	79731470
Immunoglobulins decreased	16.57	15.63	7	12786	1553	79730042
Sinus arrest	16.25	15.63	9	12784	3613	79727982
Blood thyroid stimulating hormone increased	16.15	15.63	13	12780	9695	79721900
Nail growth abnormal	15.71	15.63	5	12788	499	79731096

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H03AA02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones
ATC	H03AA03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones
FDA CS	M0021977	Triiodothyronine
FDA EPC	N0000175946	l-Triiodothyronine
CHEBI has role	CHEBI:60311	thyroid hormones
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Goiter	indication	3716002	DOID:12176
Myxedema coma	indication	21263006
Hypothyroidism	indication	40930008	DOID:1459
Myxedema	indication	43153006	DOID:11634
Congenital hypothyroidism	indication	190268003	DOID:0050328
Simple goiter	indication	267369002
Malignant tumor of thyroid gland	indication	363478007	DOID:1781
T3 Suppression for Thyroid Function Test	indication
Mild Hypothyroidism	indication
Diagnostic Test for Thyroid Dysfunction	indication
Myocardial infarction	contraindication	22298006	DOID:5844
Thyrotoxic crisis	contraindication	29028009	DOID:12837
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Osteoporosis	contraindication	64859006	DOID:11476
Diabetes mellitus	contraindication	73211009	DOID:9351
Hypopituitarism	contraindication	74728003	DOID:9406
Angina pectoris	contraindication	194828000
Osteopenia	contraindication	312894000
Primary adrenocortical insufficiency	contraindication	373662000
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Hypothyroidism	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Cytobin Tablets	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.08	acidic
pKa2	8.12	acidic
pKa3	8.77	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Thyroid hormone receptor alpha	Nuclear hormone receptor	P10827	THA_HUMAN	AGONIST	Kd	10.24	CHEMBL	CHEMBL
Thyroid hormone receptor beta	Nuclear hormone receptor	P10828	THB_HUMAN	AGONIST	Ki	10.10	CHEMBL	CHEMBL
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	6.62	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		EC50	6.30	WOMBAT-PK
Prothrombin	Enzyme	P00734	THRB_HUMAN		EC50	8.92	CHEMBL
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN		Kd	6.15	CHEMBL
Proliferating cell nuclear antigen	Nuclear other	P12004	PCNA_HUMAN		IC50	5.44	CHEMBL
THAP domain-containing protein 1	Unclassified	Q9NVV9	THAP1_HUMAN		EC50	9	WOMBAT-PK
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRP_HUMAN GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRE_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN GBRT_HUMAN		IC50	4.64	CHEMBL
Thyroid hormone receptor beta	Transcription factor		THB_RAT		IC50	8.74	CHEMBL
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		EC50	5.15	CHEMBL

External reference:

ID	Source
4022167	VUID
N0000020173	NUI
D01011	KEGG_DRUG
55-06-1	SECONDARY_CAS_RN
4018002	VANDF
4022167	VANDF
C0041014	UMLSCUI
CHEBI:18258	CHEBI
T3	PDB_CHEM_ID
CHEMBL1544	ChEMBL_ID
CHEMBL1201119	ChEMBL_ID
D014284	MESH_DESCRIPTOR_UI
DB00279	DRUGBANK_ID
2634	IUPHAR_LIGAND_ID
653	INN_ID
06LU7C9H1V	UNII
5920	PUBCHEM_CID
10814	RXNORM
1964	MMSL
4982	MMSL
d00658	MMSL
002133	NDDF
004882	NDDF
126204001	SNOMEDCT_US
350358003	SNOMEDCT_US
61275002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2178	TABLET	25 ug	ORAL	ANDA	26 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2179	TABLET	5 ug	ORAL	ANDA	26 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2180	TABLET	50 ug	ORAL	ANDA	26 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	16590-303	TABLET	50 1	ORAL	ANDA	13 sections
Liothyronine sodium	HUMAN PRESCRIPTION DRUG LABEL	1	16714-166	TABLET	5 ug	ORAL	ANDA	24 sections
Liothyronine sodium	HUMAN PRESCRIPTION DRUG LABEL	1	16714-167	TABLET	25 ug	ORAL	ANDA	24 sections
Liothyronine sodium	HUMAN PRESCRIPTION DRUG LABEL	1	16714-168	TABLET	50 ug	ORAL	ANDA	24 sections
Adthyza thyroid	HUMAN PRESCRIPTION DRUG LABEL	2	24338-016	TABLET	2.25 ug	ORAL	Unapproved drug other	24 sections
Adthyza thyroid	HUMAN PRESCRIPTION DRUG LABEL	2	24338-032	TABLET	4.50 ug	ORAL	Unapproved drug other	24 sections
Adthyza thyroid	HUMAN PRESCRIPTION DRUG LABEL	2	24338-065	TABLET	9 ug	ORAL	Unapproved drug other	24 sections
Adthyza thyroid	HUMAN PRESCRIPTION DRUG LABEL	2	24338-097	TABLET	13.50 ug	ORAL	Unapproved drug other	24 sections
Adthyza thyroid	HUMAN PRESCRIPTION DRUG LABEL	2	24338-113	TABLET	18 ug	ORAL	Unapproved drug other	24 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	33261-964	TABLET	5 ug	ORAL	ANDA	25 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	39822-0151	INJECTION, SOLUTION	10 ug	INTRAVENOUS	ANDA	25 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	39822-0151	INJECTION, SOLUTION	10 ug	INTRAVENOUS	ANDA	25 sections
Triostat	HUMAN PRESCRIPTION DRUG LABEL	1	42023-120	INJECTION	10 ug	INTRAVENOUS	NDA	25 sections
NP Thyroid 15	HUMAN PRESCRIPTION DRUG LABEL	2	42192-327	TABLET	2.25 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 15	HUMAN PRESCRIPTION DRUG LABEL	2	42192-327	TABLET	2.25 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 15	HUMAN PRESCRIPTION DRUG LABEL	2	42192-327	TABLET	2.25 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 120	HUMAN PRESCRIPTION DRUG LABEL	2	42192-328	TABLET	18 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 120	HUMAN PRESCRIPTION DRUG LABEL	2	42192-328	TABLET	18 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 120	HUMAN PRESCRIPTION DRUG LABEL	2	42192-328	TABLET	18 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 30	HUMAN PRESCRIPTION DRUG LABEL	2	42192-329	TABLET	4.50 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 30	HUMAN PRESCRIPTION DRUG LABEL	2	42192-329	TABLET	4.50 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 30	HUMAN PRESCRIPTION DRUG LABEL	2	42192-329	TABLET	4.50 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 60	HUMAN PRESCRIPTION DRUG LABEL	2	42192-330	TABLET	9 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 60	HUMAN PRESCRIPTION DRUG LABEL	2	42192-330	TABLET	9 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 60	HUMAN PRESCRIPTION DRUG LABEL	2	42192-330	TABLET	9 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 90	HUMAN PRESCRIPTION DRUG LABEL	2	42192-331	TABLET	13.50 ug	ORAL	unapproved drug other	23 sections
NP Thyroid 90	HUMAN PRESCRIPTION DRUG LABEL	2	42192-331	TABLET	13.50 ug	ORAL	unapproved drug other	23 sections